China NMPA Product Recall - Implantable cardiac pacemaker

Medtronic Inc. initiated a voluntary recall of specific models of its implantable dual-chamber pacemakers, including the Kappa 700/900, EnPulse, Adapta, Versa, Sensia, Relia, and Vitatron E/G series. This recall, reported to the National Medical Products Administration (NMPA) / State Food and Drug Administration (SFDA) of China, stems from a rare "measurement lock-up" issue. The problem, first identified in a report dated November 1, 2010, and publicized on May 16, 2011, can cause erroneous Elective Replacement Indication (ERI/RRT) and blank battery voltage readings on programmers. While the pacemaker still provides basic pacing therapy and no patient injuries have been reported, this defect could lead physicians to mistakenly believe a device needs replacement. Approximately 1.8 million affected pacemakers were manufactured globally, with 28,392 sold in China.

In response, Medtronic outlined a series of corrective actions, which commenced on May 3, 2011, with an expected completion by July 31, 2011. These actions include delivering detailed physician notification letters to explain the problem and identification methods. Furthermore, Medtronic technical representatives are dispatched immediately upon notification to reset problematic pacemakers using a specially configured programmer. This reset procedure restores normal function without requiring device removal or impacting battery life. Looking ahead, Medtronic plans a software upgrade by the end of 2011, enabling physicians to automatically reset pacemakers during routine programming to prevent future occurrences of this issue. Detailed records of these corrective activities are being maintained.